Drugs / BMS-754807
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01525823 | Feb → Apr 2012 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00898716 | Sep 2009 → Jul 2011 | neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00793897 | Apr 2009 → Jun 2012 | cancer, metastatic neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00569036 | Apr 2008 → Apr 2013 | metastatic neoplasm, neoplasm | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00908024 | Oct 2009 → Dec 2012 | colorectal cancer, head and neck cancer, metastatic neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1/2 | NCT00788333 | Jul 2009 → Nov 2011 | breast cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01225172 | Dec 2010 → Nov 2014 | breast cancer | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-754807 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01525823 ↗ |
| Known as | BMS-754807-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL575448 ↗ |
| Action | Inhibit | “Insulin-like growth factor I receptor inhibitor” CHEMBL575448 ↗ |
| Modality | Small molecule | — CHEMBL575448 ↗ |
| Route | Oral | “Tablets, Oral” NCT00569036 ↗ |
| Target | IGF1R | “Insulin-like growth factor I receptor inhibitor” CHEMBL575448 ↗ |
| Target | INSR | “Insulin receptor inhibitor” CHEMBL575448 ↗ |